Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia

Published:2013-02-19 Issue:8 Volume:27 Page:1659-1665
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Logan A C,Zhang B,Narasimhan B,Carlton V,Zheng J,Moorhead M,Krampf M R,Jones C D,Waqar A N,Faham M,Zehnder J L,Miklos D B

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201352.pdf

Reference38 articles.

1. Gribben JG, O’Brien S . Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 544–550.

2. Zenz T, Gribben JG, Hallek M, Dohner H, Keating MJ, Stilgenbauer S . Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012; 119: 4101–4107.

3. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.

4. Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956–964.

5. Rawstron AC, Bottcher S, Letestu R, Villamor N, Fazi C, Kartsios H et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013; 27: 142–149.

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting progression‐free survival from measurable residual disease in chronic lymphocytic leukemia;Clinical and Translational Science;2024-08

2. Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia;Cancers;2024-05-28

3. Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms;The Journal of Molecular Diagnostics;2023-12

4. Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia;Frontiers in Oncology;2023-04-06

5. Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia;Cancers;2023-01-06